NCT06250244View on ClinicalTrials.gov

177Lu-LNC1011 in Patients with Metastatic Castration-resistant Prostate Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

April 1, 2025

Study Completion Date

October 1, 2025

Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
DRUG

177Lu-LNC1011

\[177Lu\]Lu-LNC1011 is a novel long-circulating PSMA therapeutic probe.

Trial Locations (1)

100730

RECRUITING

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER